CSL Behring also joined the fight against the coronavirus pandemic this month when its Australian unit started working on a plasma-based therapy for patients with severe forms of COVID-19.

The ASX 200 biotech stock has lost 9% of its value since the start of the new year. The post Why is the CSL share price ...

Luckily for investors, CSL’s core plasma business Behring came to the rescue with ... Idelvion is an albumin fusion protein cited as the new standard-of-care for haemophilia B.

CSL reported a 10% lift in Behring division revenue to US$5.74 billion. This reflected a 15% jump in immunoglobulin product sales to US$3,174 million, a 9% increase in Albumin sales to US$672 ...